Status:

COMPLETED

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

Lead Sponsor:

Endo Pharmaceuticals

Conditions:

Menstrual Migraine (MM) Headaches

Eligibility:

FEMALE

18+ years

Phase:

PHASE4

Brief Summary

Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the ...

Eligibility Criteria

Inclusion

  • Had MM headaches occurring between Day -2 and Day +3 of menses
  • Had at least one year history of MM headaches
  • Had at least 8 MM headaches in the previous 12 menstrual cycles (1 year)
  • Had regular predictable menstrual periods (28 ± 4 days)

Exclusion

  • Had a history of more than 15 headache days per month
  • As part of current MM treatment, used intermittent prevention with an analgesic (e.g., naproxen for 5 days to prevent the onset of MM)
  • Had a history of myocardial infarction, ischemic heart disease (or presented with symptoms or signs compatible with ischemic heart disease), coronary vasospasm (including Prinzmetal's variant angina), other significant underlying cardiovascular disease, or peripheral vascular disease
  • Had significant cerebrovascular disease, including basilar or hemiplegic migraine
  • Had uncontrolled hypertension: systolic blood pressure \>180mmHg and diastolic blood pressure \>95mmHg
  • Had severe hepatic or renal insufficiency
  • Used an analgesic medication (including both prescription and over-the-counter) for any reason \>50% of days per month

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2006

Estimated Enrollment :

192 Patients enrolled

Trial Details

Trial ID

NCT00904098

Start Date

September 1 2005

End Date

February 1 2006

Last Update

February 15 2010

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

Stratford, Connecticut, United States

2

Clearwater, Florida, United States

3

Jacksonville, Florida, United States

4

Largo, Florida, United States